Peter Moriarty, Founder, Chief Executive Officer and Chairman of the Board of Directors, has extensive pharmaceutical industry and entrepreneurial experience. He was a founder of Shire Pharmaceuticals, and worked for Warner-Lambert and Schering-Plough earlier in his career, including management in a number of overseas locations as well as the United States. Additionally, he has founded a number of other companies focused on increasing pharmaceutical sales force productivity and enhancing pharmaceutical companies’ relationships with their physician customers by the appropriate and cost-effective use of remote communication technology.
Danilo Casadei Massari, Founder, President Europe and Head of Corporate Development, and member of the Board of Directors, has extensive experience as a senior pharmaceutical executive and as an entrepreneur. He was President and CEO of Fidia Pharmaceuticals, USA, and Director of International Corporate Development with Fidia Farmaceutici SpA. As an entrepreneur he has founded several pharmaceutical companies, including most recently, CM&D Pharma Limited, a company focused on prescription Medical Foods, which was acquired by Nestle Health Science in 2011. He is considered an expert in start-ups and co-ventures in the pharmaceutical sector.
Teo Forcht Dagi, MD, EVP, Chief Medical Officer, and member of the Board of Directors, has extensive experience both as a practicing neurosurgeon and as a venture capitalist prior to joining the founding team at Prismic. His experience also spans the areas of regulatory affairs and clinical trials. Dr. Dagi received an M.D. and M.P.H. from Johns Hopkins. He was trained in Neurosurgery and Neurophysiology at the Massachusetts General Hospital and was a Neuroresearch Foundation Fellow at Harvard Medical School. He also served as a Senior Registrar at the Neurosurgical Unit of the Guy's, Maudsley and King's College Hospitals in London, England. Also, he received an M.T.S. from Harvard, where he was appointed Joseph P. Kennedy Jr. Fellow and an MBA in Finance and Strategic Planning from the Wharton School of the University of Pennsylvania, and also holds an AB from Columbia College.
Patrick Miller, Ph.D., EVP, Strategic Planning and Analysis, has had considerable experience in the pharmaceutical industry, working with such companies as Merck where he managed Merck’s interest in the joint venture that created the first physician-level Rx database; Andrx where, as Vice President he was responsible for strategic planning and business intelligence, and Wolters Kluwer where his responsibilities included Vice President, Advanced Analytics. Dr. Miller is a graduate of the Wharton School at the University of Pennsylvania, and before commencing his business career, he was a neuroscientist and faculty member at the University of Pennsylvania, where he earned his doctorate as a Fellow at the Institute for Neurological Sciences.
Robert Ostrander, VP, Sales and Commercialization, has had a very successful sales career in the pharmaceutical industry. Having started out as a pharmaceutical sales representative, Bob rose to senior sales positions, working in such organizations as Boehringer-Ingelheim, where he was as a Regional Sales Director, and at GlaxoSmithKline where he was a Regional VP of Sales. Bob has a Bachelor of Science degree in Education from Edinboro University.
James Attley, Ph.D., VP, Business Development and Licensing, Japan and Far East, has extensive Scientific, Marketing, Business Development and Licensing experience in the international pharmaceutical industry. This includes positions as Research and Development Director at Schering-Plough in Japan; International Marketing Director at Schering-Plough’s headquarters in the USA; VP Marketing for Warner Lambert in Japan, and VP, Global Marketing at the company’s headquarters in the USA. Jim was also Senior Director for Business Development and Licensing for Japan with Schering-Plough, and Senior Director for Corporate Licensing at Merck. He earned his Ph.D. in Neuropharmacology at Liverpool University in the UK where he spent the early part of his career, including positions at Astra Pharmaceuticals and Bristol Myers before relocating to the USA.